AstraZeneca to buy Amolyt Pharma for $1.05 billion to boost rare diseases portfolio

(Reuters) – Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.

(Reporting by Eva Mathews in Bengaluru; Editing by Savio D’Souza)